Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | UBE2M | P61081 | 1/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849540 | 0.89 | OPRL1 (0.50) | OPRL1CHRM4SLC6A4OPRM1KCNH2 | |
| SCHEMBL4855793 | 0.88 | OPRL1 (0.53) | OPRL1CHRM4SLC6A4OPRM1KCNH2 | |
| SCHEMBL4849548 | 0.86 | OPRL1 (0.51) | OPRL1CHRM4SLC6A4OPRM1SLC6A2 | |
| SCHEMBL3129737 | 0.84 | SLC6A4 (0.50) | OPRL1CHRM4SLC6A4OPRM1SLC6A2 | |
| SCHEMBL2808157 | 0.83 | OPRL1 (0.56) | OPRL1CHRM4OPRM1KCNH2DRD4 | |
| SCHEMBL2834684 | 0.83 | OPRL1 (0.54) | OPRL1CHRM4SLC6A4OPRM1SLC6A2 | |
| SCHEMBL699951 | 0.82 | OPRL1 (0.63) | OPRL1CHRM4SLC6A4OPRM1DRD4 | |
| SCHEMBL2808153 | 0.81 | CHRM4 (0.57) | OPRL1CHRM4SLC6A4OPRM1KCNH2 | |
| SCHEMBL2834848 | 0.80 | SLC6A4 (0.62) | OPRL1CHRM4SLC6A4OPRM1DRD4 | |
| SCHEMBL4813486 | 0.80 | OPRL1 (0.60) | OPRL1CHRM4SLC6A4OPRM1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240670-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-7652011-B2 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070037819-A1 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | SANOFI-AVENTIS (FR) | 2007-02-15 | — | — | US | disclosed |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037819-A1 | Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine | TRPV1, IL1B, OPRK1 | OPRL1 6/4885CHRM4 790/4885SLC6A4 905/4885 |
| US-20100240670-A1 | 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | AQP4, AQP1, IL4I1 | OPRL1 1931/4885CHRM4 1750/4885SLC6A4 1101/4885 |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | OPRL1 29/4885CHRM4 183/4885SLC6A4 2182/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | OPRL1 24/4885CHRM4 135/4885SLC6A4 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.